Yu X - Search Results

1

Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy.

Yu X, Li J, Ye L, Zhao J, Xie M, Zhou J, Shen Y, Zhou F, Wu Y, Han C, Qian J, Chu T, Su C. Yu X, et al. Transl Lung Cancer Res. 2021 Sep;10(9):3782-3792. doi: 10.21037/tlcr-21-681. Transl Lung Cancer Res. 2021. PMID: 34733628 Free PMC article.

2

Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Xie M, Yu X, Chu X, Xie H, Zhou J, Zhao J, Su C. Xie M, et al. Among authors: yu x. Thorac Cancer. 2022 Feb;13(3):353-360. doi: 10.1111/1759-7714.14259. Epub 2021 Dec 27. Thorac Cancer. 2022. PMID: 34962050 Free PMC article.

3

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer.

Yu X, Chu X, Wu Y, Zhou J, Zhao J, Zhou F, Han C, Su C. Yu X, et al. Cancer Drug Resist. 2021 May 24;4(3):728-739. doi: 10.20517/cdr.2021.28. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582303 Free PMC article.

4

Immunotherapy resistance of lung cancer.

Yu X, Han C, Su C. Yu X, et al. Cancer Drug Resist. 2022 Feb 8;5(1):114-128. doi: 10.20517/cdr.2021.101. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35582531 Free PMC article.

5

Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.

Zhou J, Yu X, Hou L, Zhao J, Zhou F, Chu X, Wu Y, Zhou C, Su C. Zhou J, et al. Among authors: yu x. Lung Cancer. 2021 Mar;153:143-149. doi: 10.1016/j.lungcan.2021.01.010. Epub 2021 Jan 14. Lung Cancer. 2021. PMID: 33508527

6

Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer.

Wu J, Hou L, E H, Zhao Y, Yu X, Xu L, Ning Y, Deng J, Sun K, Zhang J, Wu C, Zhu Y, Zhao D, She Y, Su C, Chen C. Wu J, et al. Among authors: yu x. Lung Cancer. 2022 Mar;165:115-123. doi: 10.1016/j.lungcan.2022.01.019. Epub 2022 Jan 29. Lung Cancer. 2022. PMID: 35123154

7

HER2-Altered Non-Small Cell Lung Cancer: Biology, Clinicopathologic Features, and Emerging Therapies.

Yu X, Ji X, Su C. Yu X, et al. Front Oncol. 2022 Mar 29;12:860313. doi: 10.3389/fonc.2022.860313. eCollection 2022. Front Oncol. 2022. PMID: 35425713 Free PMC article. Review.

8

Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment.

Yu X, Fang C, Zhang K, Su C. Yu X, et al. Pharmaceutics. 2022 Jul 29;14(8):1581. doi: 10.3390/pharmaceutics14081581. Pharmaceutics. 2022. PMID: 36015206 Free PMC article. Review.

9

Deciphering Prognostic Value of TTN and Its Correlation With Immune Infiltration in Lung Adenocarcinoma.

Chen J, Wen Y, Su H, Yu X, Hong R, Chen C, Su C. Chen J, et al. Among authors: yu x. Front Oncol. 2022 Jul 8;12:877878. doi: 10.3389/fonc.2022.877878. eCollection 2022. Front Oncol. 2022. PMID: 35875159 Free PMC article.

10

Oncolytic Impediment/Promotion Balance Disruption by Sonosensitizer-Free Nanoplatforms Unfreezes Autophagy-Induced Resistance to Sonocatalytic Therapy.

Lu L, Wang T, Fang C, Song L, Qian C, Lv Z, Fang Y, Liu X, Yu X, Xu X, Su C, Chen F, Zhang K. Lu L, et al. Among authors: yu x. ACS Appl Mater Interfaces. 2022 Aug 17;14(32):36462-36472. doi: 10.1021/acsami.2c09443. Epub 2022 Aug 8. ACS Appl Mater Interfaces. 2022. PMID: 35939287

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34,897 results

Search Page

Filters